cyclophosphamide / Generic mfg. - LARVOL DELTA

DUET-UC-NK: Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Beijing Biotech

First-in-human • New P1 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer • NECTIN4

Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Ou Bai, MD/PHD

New P2 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • CD20 • MYC

REPROGRAM-02 : Induction Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin followed by chemotherapy in second line metastatic colorectal cancer carcinoma (clinicaltrialsregister.eu) - P2/3 | N=94 | Recruiting | Sponsor: Centre Hospitalier Regional Universitaire | Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Cancer • Oncology • Solid Tumor • BRAF

Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires (clinicaltrials.gov) - P=N/A | N=100 | Recruiting | Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Trial completion date: May 2026 ➔ May 2027 | Trial primary completion date: May 2026 ➔ May 2027

Trial completion date • Trial primary completion date • Endocrine Disorders • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • Women's Health

SOUNDTRACK-D2: AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL (clinicaltrials.gov) - P3 | N=420 | Recruiting | Sponsor: AstraZeneca

Trial initiation date • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Large B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

FLU-CART: Fludarabine exposure in patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy (clinicaltrialsregister.eu) - P4 | N=75 | Not yet recruiting | Sponsor: Universitair Ziekenhuis Gent

New P4 trial • Hematological Malignancies • Oncology

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases (clinicaltrials.gov) - P2 | N=132 | Not yet recruiting | Sponsor: Masonic Cancer Center, University of Minnesota

New P2 trial • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation • HLA-B • HLA-C • HLA-DRB1

IIT-2018-Gamma-DeltaTcell: Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide (clinicaltrials.gov) - P1 | N=38 | Recruiting | Sponsor: University of Kansas Medical Center | Trial completion date: Jan 2025 ➔ Jan 2028 | Trial primary completion date: Jan 2024 ➔ Jan 2027

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

BACON: Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

New P2 trial • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor

Congenital mesoblastic nephroma: a single-center retrospective study. (PubMed, Transl Pediatr) - "Two relapsed patients received salvage chemotherapy [vincristine-actinomycin D-cyclophosphamide (VAC) or ifosfamide-carboplatin-etoposide (ICE)], which showed limited efficacy. One relapsed patient with TPM3::NTRK1 received larotrectinib but died two months later; another with EGFR-KDD experienced disease stabilization after afatinib plus programmed cell death protein 1 (PD-1) blockade following progression on entrectinib and anlotinib...While most patients experienced favorable outcomes following surgery, relapsed cases highlight the challenges associated with molecularly atypical disease. These observations are descriptive in nature and underscore the need for larger collaborative studies to better define prognostic factors and optimal management strategies in CMN."

IO biomarker • Journal • Retrospective data • Kidney Cancer • Oncology • Pediatrics • Renal Cell Carcinoma • Solid Tumor • EGFR • ETV6 • NTRK1 • NTRK3 • TPM3

CLINICOPATHOLOGICAL CHARACTERISTICS AND PROGNOSIS OF PULMONARY–RENAL SYNDROME IN COASTAL SOUTH INDIA (ISN-WCN 2026) - "Treatment with Rituximab was not superior to cyclophosphamide, though both improved outcomes when used along with plasmapheresis. Overall survival correlated best with initial organ damage, underscoring the importance of early diagnosis and treatment."

Clinical • ANCA Vasculitis • Chronic Kidney Disease • Glomerulonephritis • Inflammatory Arthritis • Lupus Nephritis • Nephrology • Renal Disease • Vasculitis

MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (MPGN): SHORT-TERM CLINICOPATHOLOGICAL FEATURES AND OUTCOMES — A SINGLE-CENTER STUDY (ISN-WCN 2026) - "Immunosuppression with steroids and cyclophosphamide was administered to 70% of patients.Patients were divided into two groups: those requiring dialysis (13) and those managed conservatively (74)...Nearly half of the patients had crescentic involvement, and many required dialysis at presentation. As most patients had immune-complex–mediated MPGN likely triggered by subclinical infections, renal improvement may have occurred spontaneously, aided by the resolution of the underlying immune response."

Clinical • Chronic Kidney Disease • Glomerulonephritis • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Lupus Nephritis • Nephrology • Urology

FALSE POSITIVE ANTI-GBM ANTIBODIES IN A PATIENT WITH BOVINE BIOPROSTHESIS PRESENTING WITH PULMONARY HAEMORRHAGE: A CASE REPORT (ISN-WCN 2026) - "In view of persistent pulmonary haemorrhage and the risk of isolated pulmonary anti-GBM disease, empirical treatment with plasma exchange, intravenous methylprednisolone, and cyclophosphamide was commenced, while awaiting confirmatory testing. Clinicians should recognize that bovine bio-prostheses can induce cross-reactive antibodies, producing false-positive anti-GBM serology. Confirmatory testing and multidisciplinary correlation are essential."

Case report • Clinical • Glioblastoma • Glomerulonephritis • Immunology • Lupus Nephritis • Nephrology

EVALUATION OF RENAL OUTCOMES IN IGA NEPHROPATHY PATIENTS IN THE NATIONAL KIDNEY AND TRANSPLANT INSTITUTE RECEIVING SGLT2 INHIBITOR TREATMENT VERSUS STANDARD OF CARE — A RETROSPECTIVE STUDY (ISN-WCN 2026) - "The standard treatment protocol for individuals with IgA nephropathy includes using supportive measures such as lifestyle intervention, medications inhibiting renin-angiotensin-aldosterone system (RAAS), fish oil, with or without any immunosuppressive agents like steroids, azathioprine, mycophenolate mofetil, cyclophosphamide, or rituximab. Standard treatment led to higher progression to renal replacement therapy. SGLT2 inhibitors combined with standard therapy and supportive care, provide enhanced kidney protection in IgA nephropathy."

Retrospective data • Glomerulonephritis • IgA Nephropathy • Inflammation • Lupus Nephritis • Renal Disease • Transplantation

BEYOND DIABETES: WHEN NEPHROTIC SYNDROME IS NOT DIABETIC NEPHROPATHY IN A PATIENT WITH LONG STANDING TYPE TWO DIABETES MELLITUS (ISN-WCN 2026) - "Her medications included biphasic human insulin 20 units in the morning and 12 units at night, empagliflozin 10mg daily, vildagliptin/metformin 50/500 once daily, telmisartan 40 mg once daily, and atorvastatin 80 mg at night .Glycemic control was sub-optimal (HbA1c 7.8%) and fundoscopy revealed no evidence of diabetic or hypertensive retinopathy.She reported intermittent joint pains without arthritis or constitutional symptoms.On examination, she was hemodynamically stable with bilateral pedal edema...There was no evidence of diabetic nephropathy, confirming primary membranous nephropathy.The patient was initiated on the modified Ponticelli regimen, consisting of oral corticosteroids alternating with oral cyclophosphamide...A high index of suspicion, serologic workup, and renal biopsy helped uncover primary membranous nephropathy in a diabetic patient, allowing timely immunosuppressive therapy with promising early response. Clinicians should, therefore, maintain..."

Clinical • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Diabetic Retinopathy • Glomerulonephritis • Hypertension • Immunology • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Nephrology • Orthopedics • Renal Disease • Retinal Disorders • Type 2 Diabetes Mellitus

RENAL BIOPSY IN MULTIPLE MYELOMA: AN OLD QUESTION WITH A NEW ANSWER; AN UPDATED ONCONEPHROLOGY MODEL. (ISN-WCN 2026) - "She started chemotherapy with cyclophosphamide, bortezomib, dexamethasone, and follow up showed complete remission.The patient referred to onconephrology clinic for evaluation as a candidate for HSCTx. We advocate an updated onconephrology model in which onconephrology should shift from reactive consultation to full-cycle oversight: early diagnosis and biopsy, CKD-EPI–based chemotherapy dosing, vigilant renal monitoring and injury management, selective prognostic biopsy, and targeted HSCTx referral to maximize kidney outcomes. There is a need for a full comprehensive section dedicated to MM in forthcoming KDIGO guidelines."

Biopsy • Chronic Kidney Disease • Glomerulonephritis • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Pulmonary Disease • Renal Disease

RETROSPECTIVE EVALUATION OF CLINICAL AND ECONOMIC OUTCOMES IN IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA PATIENTS TREATED WITH OR WITHOUT CAPLACIZUMAB (ISN-WCN 2026) - "And all patients in the non-Cap group and 4 out of 5 patients in the Cap group received rituximab. One patient in the Cap group received cyclophosphamide...The total cost of PE and Cap tended to be higher in the Cap group (3816 [3278-5577] vs. 20051 [9425-34731] ×103 yen, p=0.07).Conclusion The Cap group showed a significantly shorter time to platelet recovery, not time to ADAMTS13 remission. Despite reductions in the number of PE sessions, the cost of PE and Cap was higher in the Cap group, primarily due to the high cost of Cap."

HEOR • Retrospective data • Hematological Disorders • Rare Diseases • Thrombocytopenic Purpura

SUBARACHNOID HEMORRHAGE AND CEREBRAL INFARCTION IN ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE: A CASE REPORT AND REVIEW OF THE LITERATURE (ISN-WCN 2026) - "Despite persistently elevated antibody titers refractory to corticosteroids and plasma exchange (PE), rituximab (RTX) induction achieved a stable and sustained decline in antibody levels.Methods A 53-year-old woman presented with fever, headache, and progressive renal dysfunction...She received intravenous methylprednisolone pulse followed by oral prednisolone and PE...The current standard treatment for anti-GBM disease includes PE, corticosteroids, and cyclophosphamide (CYC)...Clinicians should be alert to potential neurological involvement in anti-GBM disease. Furthermore, our case suggests that RTX may serve as a therapeutic option when conventional therapy fails to sufficiently reduce antibody titers."

Case report • Clinical • Review • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Epilepsy • Hypertension • Infectious Disease • Infertility • Nephrology • Renal Disease • Sexual Disorders • Subarachnoid Hemorrhage • CRP

SUCCESSFUL TREATMENT OF LUPUS NEPHRITIS BY SWITCHING FROM BELIMUMAB TO TELITACICEPT: A CASE ANALYSIS (ISN-WCN 2026) - "She was treated orally with methylprednisolone, mycophenolate mofetil, and hydroxychloroquine...After discharge, she was prescribed oral prednisone acetate 6 tablets/day, which gradually reduced to 2 tablets/day after 6 months; combined with cyclophosphamide 0.8g/month (cumulative dose 4.8g); combined with telitacicept 160mg/week; and irbesartan 150mg, once daily.Results January 2025: C3: 0.71 g/L, C4: 0.11 g/L; 24-hour urine protein quantification: 1738.8 mg/24h; serum creatinine: 71 μmol/L, eGFR: 83.56 mL/min.March 2025: C3: 0.71 g/L, C4: 0.12 g/L; 24-hour urine protein quantification: 1112.8 mg/24h; serum creatinine: 70 μmol/L, eGFR: 84.41 mL/min.April 2025: C3: 0.97 g/L, C4: 0.17 g/L; 24-hour urine protein quantification: 560 mg/24h; serum creatinine: 70 μmol/L, eGFR: 84.41 mL/min; anti-dsDNA antibody: 59.67 IU/mL; ANA (titer): 1:320.June 2025: 24-hour urine protein quantification: 324 mg/24h; serum creatinine: 79 μmol/L, eGFR: 82.98 mL/min.No significant adverse..."

Clinical • Alopecia • Fibrosis • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

CHRONIC HEMODIALYSIS FOLLOWING REFRACTORY NEPHROTIC SYNDROME AND DIURETIC RESISTANCE: A CASE REPORT (ISN-WCN 2026) - "Immunosuppressive therapy with prednisone, mycophenolate mofetil, and cyclophosphamide was ineffective. Three months later, he relapsed with proteinuria 17 g/24 h and anasarca, receiving rituximab (1 g every 15 days), tacrolimus, and combined diuretic therapy (furosemide, spironolactone, acetazolamide, chlorthalidone, dapagliflozin) without improvement...In his final hospitalization, he developed an axillary abscess, hyperosmolar hyperglycemic state, and acute-on-chronic renal failure (creatinine 5.5 mg/dL), refractory to diuretics, requiring hemodialysis with no renal recovery.Download: Download high-res image (643KB)Download: Download full-size imageDownload: Download high-res image (257KB)Download: Download full-size imageConclusion RNS complicated by diuretic resistance may progress to irreversible ESRD despite intensive immunosuppression and multidrug diuretic regimens. Early recognition of treatment failure and timely initiation of renal replacement therapy are..."

Case report • Clinical • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Glomerulonephritis • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

CAPLACIZUMAB IS EFFECTIVE IN ACHIEVING EARLY PLATELET RECOVERY AND MAINTAINING STABILITY IN IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA WITH POST–PLASMA EXCHANGE REBOUND OF ANTI-ADAMTS13 ANTIBODIES: CASE SERIES (ISN-WCN 2026) - "All patients received PE (1.1–1.5 plasma volumes per session, replaced with fresh-frozen plasma), prednisolone, rituximab, and caplacizumab. P5 additionally received cyclosporine, and P6 received cyclophosphamide...These observations suggest that, in addition to platelet count, serial monitoring of ADAMTS13 activity and inhibitor titers is critical for assessing disease activity. Caplacizumab may help maintain platelet count stability during transient inhibitor rebound, but careful immunologic follow-up is warranted to guide treatment optimization."

Clinical • Hematological Disorders • Thrombocytopenic Purpura

CONCURRENT ANCA-ASSOCIATED VASCULITIS AND IGG4-RELATED DISEASE: A CASE OF OVERLAP SYNDROME (ISN-WCN 2026) - "Treatment with corticosteroids and cyclophosphamide improved renal function and systemic symptoms, highlighting the need for integrated diagnosis and therapy in overlap syndromes.Conclusion The overlap of ANCA-associated vasculitis and IgG4-related disease is rare but crucial to recognize for optimal treatment. Research into shared mechanisms will improve understanding and management of autoimmune diseases."

Clinical • ANCA Vasculitis • Cardiovascular • Fibrosis • Glomerulonephritis • Hypotension • Infectious Disease • Inflammation • Lupus Nephritis • Nephrology • Rare Diseases • Renal Disease • Respiratory Diseases • Tuberculosis • Vasculitis

A CASE OF ANTI-GLOMERULAR BASEMENT MEMBRANE NEPHRITIS DEVELOPING FIVE EPISODES OF LATE-ONSET NEUTROPENIA AFTER RITUXIMAB ADMINISTRATION (ISN-WCN 2026) - "Filgrastim was administered, resulting in rapid recovery. We report a rare case of five episodes of LON after a single RTX administration. In patients with anti-GBM nephritis, careful monitoring for LON is warranted after treatment with cyclophosphamide and rituximab."

Clinical • Glomerulonephritis • Hematological Disorders • Inflammation • Lupus Nephritis • Nephrology • Neutropenia • CRP

PODOCYTIC INFOLDING GLOMERULOPATHY IN PHOSPHOLIPASE A2 RECEPTOR-POSITIVE MEMBRANOUS NEPHROPATHY: REPORT OF THREE CASES (ISN-WCN 2026) - "Two patients showed only a partial response to the first agent (one to cyclophosphamide and one to rituximab), prompting treatment to be switched. The nature of PIG remains controversial, as it is uncertain whether it represents a distinct pathological entity or a morphological pattern associated with certain, mainly autoimmune, diseases. The cause of podocyte injury in this disease remains to be elucidated in the future."

Clinical • Glomerulonephritis • Immunology • Renal Disease

TREATMENT OUTCOMES AND RELAPSE PREDICTORS IN ADULT MINIMAL CHANGE DISEASE AT A TERTIARY CENTER IN ETHIOPIA (ISN-WCN 2026) - "Younger age (mean 23 ± 5 years, p = 0.047), lower baseline albumin (2.60 ± 0.29 g/dL, p = 0.01), and higher total cholesterol (298 ± 100 mg/dL, p = 0.001) were significantly associated with relapse.VariablesFrequencyPercentage %Oral PrednisoloneYes36100.0%No00.0%Response to initial steroid responsiveYes3288.9%No411.1%Initial Steroid DependentYes822.2%No2877.8%Initial Steroid ResistanceYes411.1%No3288.9%Tx options and duration of tx for steroid dependentCyclosporine225.0%Rituximab675.0%Cyclophosphamide00.0%Other00.0%Tx outcome for steroid dependentCR8100.0%PR00.0%Tx options and duration of tx for steroid resistanceCyclosporine466.7%Cyclophosphamide233.3%Tx outcome for steroid resistanceCR4100.0%PR00.0%Time to complete remission for steroid dependent estimated in weeksMean 7.5 WeeksSD ± 4.2 weeksConclusion One-third of adult MCD patients experienced relapse, with younger age, hypoalbuminemia, and hypercholesterolemia identified as key predictive..."

Clinical • Dyslipidemia • Glomerulonephritis • Metabolic Disorders